Jefferies is out with a preview of earnings for Bristol-Myers Squibb BMY.
In a note to clients, Jefferies writes, "We forecast 2010E revenues to grow 3% (+3% CER) to $19.35bn (Cons $19.42bn) with an estimated neutral FX impact. We model a higher gross margin of 73.8% versus 73.3% in 2009 primarily reflecting FX movements during 2010. We anticipate higher R&D costs (+4% YoY; Medarex integration), which are expected to be offset by lower MS&A (-2% YoY) and A&P costs (-11% YoY) due to the change in the Otsuka partnership agreement. As a result, we expect the operating margin to improve by 223bps to 32.1% compared to 29.9% in 2009. After assuming a slightly higher tax rate of 22.9% versus 22.2% in 2009 and a 13% decline in the average share count for 2010E, we expect 2010E EPS to increase by 18% YoY to $2.17 (Cons $2.16) versus guidance of $2.10 to $2.20."
Jefferies maintains Buy with a $28.50 PT on BMY.
BMY is trading today at $25.95, up 0.46% from yesterday's close.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
---|
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in